CompletedPhase 2NCT04502381
Combined Inhalational With Intravenous Amphotericin B Versus Intravenous Amphotericin B Alone for Pulmonary Mucormycosis
Studying Zygomycosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
- Principal Investigator
- Ratnakara Rao, MBBS, MDPost Graduate Institute of Medical Education and Research, Chandigarh
- Intervention
- Inhaled amp B deoxycholate+intravenous liposomal amp B(drug)
- Enrollment
- 30 target
- Eligibility
- 12 years · All sexes
- Timeline
- 2020 – 2021
Study locations (1)
- Post graduate Institute medical education and research, Chandigarh, India
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04502381 on ClinicalTrials.govOther trials for Zygomycosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07339800Chest CT Scan in Pulmonary Mucormycosis: Prognostic ValueUniversity Hospital, Strasbourg, France
- ACTIVE NOT RECRUITINGNCT07191756Amphotericin B Versus Isavuconazole for Mucormycosis: A Comparative Efficacy and Safety StudyQiu Ye
- RECRUITINGNCT07185503Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and SafetyInstitute of Hematology & Blood Diseases Hospital, China
- ACTIVE NOT RECRUITINGNCT06515743Rehabilitation With an Obturator in Maxillary DefectsMenoufia University
- RECRUITINGNCT05406037Biomarkers for Invasive MucormycosisUniversity Hospital, Lille
- RECRUITINGPHASE2NCT05468372Amphotericin Versus Posaconazole for Pulmonary MucormycosisPost Graduate Institute of Medical Education and Research, Chandigarh